[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 33, "maxAge": 86400, "priceHint": 4, "previousClose": 3.89, "open": 3.86, "dayLow": 3.72, "dayHigh": 3.995, "regularMarketPreviousClose": 3.89, "regularMarketOpen": 3.86, "regularMarketDayLow": 3.72, "regularMarketDayHigh": 3.995, "beta": 0.714, "forwardPE": -0.07653846, "volume": 1126410, "regularMarketVolume": 1126410, "averageVolume": 1076956, "averageVolume10days": 2082600, "averageDailyVolume10Day": 2082600, "bid": 3.92, "ask": 4.02, "bidSize": 300, "askSize": 300, "marketCap": 608159936, "fiftyTwoWeekLow": 1.07, "fiftyTwoWeekHigh": 4.5, "priceToSalesTrailing12Months": 60.815994, "fiftyDayAverage": 3.2049, "twoHundredDayAverage": 2.692175, "currency": "USD", "enterpriseValue": 2743861248, "profitMargins": -2.6341, "floatShares": 457889543, "sharesOutstanding": 152804000, "sharesShort": 2212018, "sharesShortPriorMonth": 2767401, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.015800001, "heldPercentInsiders": 0.00509, "heldPercentInstitutions": 0.56259, "shortRatio": 2.72, "shortPercentOfFloat": 0.019, "impliedSharesOutstanding": 140243008, "bookValue": 0.306, "priceToBook": 13.0065365, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -26341000, "trailingEps": -0.15, "forwardEps": -52.0, "enterpriseToRevenue": 274.386, "enterpriseToEbitda": -109.584, "52WeekChange": 2.2357724, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MREO", "underlyingSymbol": "MREO", "shortName": "Mereo BioPharma Group plc", "longName": "Mereo BioPharma Group plc", "firstTradeDateEpochUtc": 1556112600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2bb59234-2dd4-3418-a5f3-ada28f11788c", "messageBoardId": "finmb_307970474", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.98, "targetHighPrice": 7.96, "targetLowPrice": 5.97, "targetMeanPrice": 7.16, "targetMedianPrice": 6.96, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 48660000, "totalCashPerShare": 0.07, "ebitda": -25039000, "totalDebt": 6019000, "quickRatio": 4.572, "currentRatio": 4.862, "totalRevenue": 10000000, "debtToEquity": 14.051, "revenuePerShare": 0.074, "returnOnAssets": -0.20591, "returnOnEquity": -0.55902, "freeCashflow": -12143018, "operatingCashflow": -19875000, "grossMargins": 0.7079, "ebitdaMargins": -2.5039, "operatingMargins": -2.5648, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]